Enrollment has been completed for this study to create a dedicated skin tone scale to better categorize skin tones.
Aesthetic Solutions is an active research center, partnering with pharmaceutical and medical device manufacturers to bring the latest treatments to our patients and advance safe, effective aesthetic treatments.
Enrollment has been completed for this study to create a dedicated skin tone scale to better categorize skin tones.
Enrollment has been completed for this study to evaluate the effectiveness and safety of a new neuromodulator to reduce glabellar lines.
Enrollment has been completed for this study that aims to evaluate the safety and efficacy of an investigational biostimulator product when used to treat wrinkles and improve overall skin appearance in décolletage area.
This research study is looking to collect post-market data on an already FDA approved device for subcutaneous fat reduction.
This study aims to evaluate the safety and efficacy of an already FDA approved neuromodulator when used to treat Platysma Prominence (visible vertical neck bands and jawline appearance). The use of the study drug is investigational for this study.
Dr. Cox served as Principal Investigator for this study aiming to assess changes in scalp and hair health using (plated) topical exosome serum among menopausal and postpartum females with self-perceived thinning hair and eyebrows. Additionally, a topical exosome serum was used on the face to evaluate effects on aging facial skin. This study began May 2025 and ended February 2026.
Dr. Cox served as Principal Investigator for Psychometric Validation and Cognitive Interviews of the Abbvie Face and Neck Core Concept Scales.
Dr. Cox served as Principal Investigator for this multicenter, randomized, double-blind, placebo-controlled, single-dose Phase 2 Study evaluating the safety and efficacy of JTM201 (Botulinum toxin type A) to treat moderate or severe glabellar lines. The study began in April 2023 and concluded in August 2025.
Dr. Cox served as Principal Investigator on this clinical trial “A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0116 for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds.” This is for a new filler that is not yet FDA approved. Dr. Cox was very impressed with this new product and we hope to see it on the market soon! This study began February 20223 and ended February 2026.
Dr. Cox is completed work to develop a patient-reported outcome skin laxity scale. This began in August 2023 and ended in 2024.
Dr. Cox is served as Principal Investigator for this randomized, blinded evaluator, no-treatment control, multicenter, prospective, clinical study of RHA®4 for the correction of sagging jawline. RHA4 produces beautiful results along the jawline, and we were happy to see this area being evaluated. This study began in September 2023 and ended in February 2026.
Dr. Cox completed work as Principal Investigator for this study evaluating the efficacy, safety, and tolerability of a new injectable product to reduce belly fat. Dr. Cox found mixed results with this product. We hope to see more innovations in this exciting new area of noninvasive fat reduction. This study began in May 2023 and completed in December 2024.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for Abdominal Fat. This was completed in July of 2022.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for the Forehead. This was completed in February of 2022.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for the Crow’s Feet. This was completed in February of 2022.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for Temple Volume Deficit. This was completed in September of 2022.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for Chin Retrusion. This was completed in September of 2022.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale. This was completed in 2022.
Dr. Cox completed work as Principal Investigator for the study A Randomized, no-treatment-controlled, evaluator-blinded, multi-center study to evaluate the effectiveness and safety of Restylane Contour in the treatment of temple hollowing.
Dr. Cox has long been using HA filler in the temple region to correct hollowing, improve overall facial contour and lift the brow. We hope to see this indication approved and more widely used in practice! This study began in March 2023 and ended in February 2025.
Dr. Cox completed work as Principal Investigator for this study evaluating the effectiveness and safety of a new injectable filler (Galderma GP109) for jawline definition. This study began in August 2022 and ended in November 2024. We hope to see this product on the market in the future!
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for the Jawline. This was completed in September of 2022.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for a new device. This was completed in March of 2020.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for the Tear Trough. This was completed in February of 2017.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for the Temples. This was completed in February of 2017.
Dr. Cox served as an Independent Reviewer for the Development & Validation of a Photonumeric Scale for Platysma Bands. This was completed in June of 2018.
Questions? Text (919) 403-6200 to schedule or chat.
Aesthetic Solutions Will Be Closed Friday, 7/3/26, and reopen monday, 7/6/26.
For Medical emergencies, please call 911.
To reach the provider on call or to leave a message for our administrative team regarding an appointment, call 919-403-6200.